HHS-NIH-NIAID-BAA2020-1 Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections, and Emerging Infectious Diseases Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical

HHS-NIH-NIAID-BAA2020-1 Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Supports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses

HHS-NIH-NIAID-BAA2020-1 Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases Supports advancing the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness. Number of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up

Innovators within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from